6.1.2025 14:57:26 CET | Thor Medical ASA | Annen informasjonspliktig
regulatorisk informasjon

Oslo, Norway, 6 January 2025

Reference is made to stock exchange announcement by Thor Medical ASA (the
"Company") on 16 December 2024 regarding the notice of an extraordinary general
meeting of the Company and the stock exchange notice on 12 December 2024
regarding the completion of a private placement (the "Private Placement"). 

The extraordinary general meeting in the Company was held today 6 January 2025.
All items on the agenda were approved by the general meeting as proposed the
board, including i) the issuance of the 23,396,380 new shares (the "Offer
Shares") in tranche 2 ("Tranche 2") of the Company's completed Private
Placement, and ii) granting the board of directors an authorisation to increase
the Company's share capital by up to NOK 2,200,000, in connection with the
contemplated subsequent offering (the "Subsequent Offering").

The Offer Shares is expected to be issued and registered in the Norwegian
Register of Business Enterprises after the Company has published a prospectus
for the listing of the Offer Shares. The prospectus is expected to be published
on or about 10 January 2025.

Settlement of the Offer Shares in Tranche 2 is expected to take place on or
about 8 January 2025. The Offer Shares will be settled through a delivery versus
payment transaction with existing and unencumbered shares in the Company that
are admitted to trading on Euronext Oslo Børs pursuant to a share lending
arrangement between the Company, Carnegie AS and Scatec Innovation AS as the
lender.

A detailed description of the Subsequent Offering, including the terms and
conditions, as well as factors to consider when subscribing for shares in the
Subsequent Offering, will be disclosed in an offer and listing prospectus to be
published before the start of the subscription period for the Subsequent
Offering. It is expected that the subscription period for the Subsequent
Offering will last from 13 January 2025 at 09:00 (CET) to 24 January 2025 at
12:30 (CET), pending the approval and publication of the prospectus.

After the general meeting, the chairperson of the board of the Company, Ludvik
Sandnes, informed the participants that he had notified the Company's nomination
committee of his decision not to seek re-election at the annual general meeting
of the Company.

The minutes are attached hereto and are also available on 
https://www.thormedical.no/.



DISCLOSURE REGULATION

This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, 
   brede.ellingseter@thormedical.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

VEDLEGG

Last ned som PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18375155/5503/Last%20ned%20som%20
PDF.pdf

Minutes from extraordinary general meeting 6 January 2025.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18375155/5502/Minutes%20from%20ex
traordinary%20general%20meeting%206%20January%202025.pdf